|
A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma. |
| |
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis Canada Pharmaceuticals Inc; Pierre Fabre; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche |
| |
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche; Sanofi |
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD; Pierre Fabre; Sun Pharma |
Research Funding - 4SC (Inst); Amgen (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Idera (Inst); Immunocore (Inst); Novartis (Inst); Philogen (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Pierre Fabre |
| |
|
|
Stock and Other Ownership Interests - BioNTech |
Patents, Royalties, Other Intellectual Property - BioNTech |
| |
|
|
Stock and Other Ownership Interests - BioNTech |
Patents, Royalties, Other Intellectual Property - BioNTech |
| |
Robert Alexander Jabulowsky |
|
Stock and Other Ownership Interests - BioNTech |
Patents, Royalties, Other Intellectual Property - BioNTech |
| |
|
|
| |
Doreen Schwarck-Kokarakis |
|
Stock and Other Ownership Interests - BioNTech |
Patents, Royalties, Other Intellectual Property - BioNTech |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - BioNTech |
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AAA HealthCare; Ipsen; Janssen |
Consulting or Advisory Role - GlaxoSmithKline; Novartis |
| |
|
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche |
| |
|
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi |
Research Funding - Apogenix (Inst); Elsalys Biotech (Inst); Noxxon Pharma (Inst); TILT Biotherapeutics (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi |
| |
|
Consulting or Advisory Role - AstraZeneca; Biogen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Leo Pharma; Lilly; MSD; Novartis; Regeneron; Roche; Tigercat Pharma; UCB |
Speakers' Bureau - AstraZeneca; Biogen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Leo Pharma; Lilly; MSD; Novartis; Regeneron; Roche; Tigercat Pharma; UCB |
| |
|
Honoraria - Merz GmbH; Roche |
Consulting or Advisory Role - Actelion; Amgen; Bristol-Myers Squibb; ICON Clinical Research; Novartis; Regeneron; Roche |
Research Funding - Abbvie; Almirall; Amgen; Biogen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Galderma; GlaxoSmithKline; Idea Pharma; Leo Pharma; Lilly; Medac; Merck; Mitsubishi Chemical Medience Corporation; MSD; Novartis; Pfizer; Regeneron; Roche; Sandoz; Schering-Plough; Tigercat Pharma; UCB |
| |
|
Employment - BioNTech; BioNTech (I) |
Leadership - BioNTech; BioNTech (I) |
Stock and Other Ownership Interests - BioNTech; BioNTech (I) |
Patents, Royalties, Other Intellectual Property - BioNTech; BioNTech (I) |
| |
|
No Relationships to Disclose |